IPO
IPO
Best Performers
Forthcoming Issues
Closed Issues
New Listings
Current Issues
IPO Performance
IPO News
IPO Analysis
Basis of Allotment
Draft Prospectus
  HOME  >  IPO  >   IPO SNAPSHOT
IPO Snapshot    
Tatva Chintan Pharma Chem Ltd.
Issue Open Date 16-Jul-21  
Issue Closing Date 20-Jul-21  
Application Money 100  
Allotment Money  
Price Band 1073 - 1083  
Minimium Application No. 13  
Issue Size (Shares) 4616804  
Market Lot 1.00  
Objective
1. Funding capital expenditure requirements for expansion of our Dahej Manufacturing Facility.2. Funding capital expenditure requirements for upgradation at our R&D facility in Vadodara.3. General corporate purposes.
Category No. of Shares No. of Shares Subscription Ratio
  Offered / Reserved Bid For  
Non-Institutional Investors   698975   358028073   512.22  
Qualified Institutional Buyers   931966   172628313   185.23  
Retail Individual Investors   1630941   57639855   35.34  
Business Description
We are a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio ofstructure directing agents (“SDAs”), phase transfer catalysts (“PTCs”), electrolyte salts for super capacitorbatteries and pharmaceutical and agrochemical in
more...
Promoter's Holding
Total Share Capital   20087500  
Offered to Public   4616804  
Promoter's Holding (Pre-Issue)   100  
Promoter's Holding (Post-Issue)   79.17  
Address
Plot No 502/17
G I D C Estate
Ankleshwar
Bharuch ,
Gujarat ,
393002
Phone: 07574848533 / 34
Email: chintan@tatvachintan.com
Website: www.tatvachintan.com
Registrar
Link Intime India Pvt Ltd.
C 101
247 Park
LBS Marg
Vikhroli (West)
Mumbai
Listed at
BSE, NSE
Lead Manager
ICICI Securities Ltd
JM Financial Ltd.
Promoters
Ajaykumar Mansukhlal Patel
Chintan Nitinkumar Shah
Shekhar Rasiklal Somani
Back Back TopTop
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Awareness & Information | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.